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Background: In multiple sclerosis patients, the persistence of, and adherence to, disease-modifying 
treatment are often insufficient. The degree of persistence and adherence may relate to the care 
received from various disciplines.
Methods: In an observational study of 203 patients treated with glatiramer acetate 20 mg 
subcutaneous daily, we assess the persistence and adherence in relation to the amount of care 
received in various disciplines. The frequencies and durations of care per discipline were 
reported by patients online, as were missed doses and eventual treatment discontinuation. The 
associations between the care provided by neurologists, nurses, psychologists, pharmacists, and 
rehabilitative doctors and persistence and adherence were the primary outcomes; the associa-
tions between care received from general practitioners, occupational therapists, physiotherapists, 
social workers, dieticians, home caregivers, informal caregivers, other medical specialists, and 
other caregivers and persistence and adherence were secondary outcomes.
Results: It was found that the 12-month persistence rate was 62% and that 85% of the persistent 
patients were 95% adherent (missed ,5% of doses). Patients who discontinued treatment in the 
fourth quarter (Q) had received less-frequent and shorter psychological care in Q3 than persistent 
patients (P=0.0018 and P=0.0022). Adherent patients had received more frequent home care 
and informal care than nonadherent patients (P=0.0074 and P=0.0198), as well as longer home 
care and informal care (P=0.0074 and P=0.0318). Associations between care in other disciplines 
and persistence or adherence were not observed. As to the relationship between adherence and 
persistence, nonadherence in Q2 was related to discontinuation after Q2 (P=0.0001).
Conclusion: We obtained no evidence that, in multiple sclerosis patients, persistence of and 
adherence to disease-modifying treatment are associated with the amount of neurological, 
nursing, pharmaceutical, or rehabilitative care. However, findings suggest that the treatment of 
psychological problems in Q3 may relate to persistence and that home care and informal care 
may relate to adherence.
Keywords: home care, informal care, nursing, pharmaceutical, rehabilitative, psychological
Introduction
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and degenerative 
disease of the central nervous system, for which no definite cure is available. In about 
the first 20 years of the disease, most patients show a relapsing–remitting (RR) course, 
during which incomplete remissions often cause stepwise increases in disability. Glati-
ramer acetate (GA), interferon-beta (INFβ)-1a, and INFβ-1b are first-line, parenterally 
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administered, disease-modifying drugs (DMDs) for RRMS 
that reduce relapses and disability progression.1 Postauthori-
zation studies showed that treatment with injectable DMDs is 
associated with an increase in health-related quality of life2,3 
and that, in the long term, these drugs may indeed prevent or 
delay an increase in disability and a conversion to secondary 
progressive MS.4
In general, medication for chronic illness is only taken 
by 50%–60% of the patients as prescribed.5,6 Not taking 
medication as prescribed includes the following two differ-
ent patient behaviors: premature treatment discontinuation 
(nonpersistence) and missing doses (nonadherence).6 There 
is evidence that, in RRMS, high DMD exposure is associated 
with better clinical outcomes than low DMD exposure,7,8 
which means that a continuous use and a minimum of missed 
doses provide the greatest clinical benefit.9,10
Discontinuation of disease-modifying treatment mostly 
occurs in the first 12 months.9–11 At 4 months, up to 11% of 
RRMS patients treated with injectable DMDs have discon-
tinued treatment,12 and after 6 months, figures vary from 9% 
to 27%.13 However, discontinuation rates in MS-specialized 
academic centers were only 1.7% after 6 months and 8% after 
2 years,14 suggesting that persistence may relate to qualitative 
or quantitative aspects of care; MS-specialized centers often 
provide care from multiple disciplines, whereas care may be 
more limited in hospitals without a special interest in MS. 
Data on the percentages of missed DMD doses in RRMS 
vary. In MS patients with two or more DMD dispensings, 
the mean medication possession ratio was found to be 68% 
for a 2-year period.11 In contrast, sc INFβ-1a-treated patients, 
where an electronic autoinjector is used with real-time record-
ing of injections, showed a mean adherence of 95% over a 
period of 1.5 (SD 1.0) years.12
According to the World Health Organization 2003 report6 
and a recent Cochrane Review, 18 multidisciplinary interven-
tions may improve both adherence and persistence. There-
fore, detailed knowledge on which care disciplines and what 
amounts of care are associated with persistence and adherence 
could help to optimize the multidisciplinary care in RRMS 
patients starting a DMD and could also guide the development 
of persistence- and adherence-promoting measures.
In view of the details described we decided to assess in 
RRMS patients who started parenteral DMD treatment, the 
relationship between multiple disciplines of care, and persis-
tence and adherence. As INFβ and GA have clearly different 
side effect profiles and injection frequencies and as both these 
aspects are likely to influence persistence and adherence, we 
chose to study patients treated with one type of DMD, thus 
guaranteeing a homogeneous study population. Because 
pilot data on discontinuation and risk factors were available 
for patients treated with GA 20 mg subcutaneous (sc) daily 
in the Netherlands,13 it was decided to study patients starting 
treatment with GA 20 mg sc daily. We hypothesized that early 
discontinuation or missing doses were related to less-frequent 
neurological, nursing, psychological, pharmaceutical, or 
rehabilitative care contacts or shorter care duration in one or 
more of these disciplines.
Materials and methods
study design
The methods and design of the study have been described 
in detail.13 In brief, the Correlative Analysis of Adherence 
in RRMS (CAIR) study was an investigator-initiated, pro-
spective, web-based, patient-centered, observational study 
in the Netherlands. The primary objective was to investigate 
whether persistence of and adherence to daily treatment 
with GA 20 mg sc daily was associated with the quantity of 
care received from certain predetermined disciplines. The 
study duration was 12 months (Nederlands Trial Register 
code: TC2432). GA was prescribed by neurologists as per 
regular care and dispensed as a commercial drug by general 
pharmacies (Copaxone®). GA was administered according 
to the instructions in the package leaflet. The recruitment 
period was from July 2009 to July 2011. The inclusion cri-
teria for participation were as follows: 1) indication for GA 
treatment, 2) being relapse free and having stable symptoms 
for at least 30 days, 3) willing and able to comply with the 
protocol, 4) having given informed consent, and 5) having 
access to the Internet. The exclusion criteria were as follows: 
1) contraindication for GA as defined in the “Summary of 
product characteristics”15 text, 2) hypersensitivity to GA or 
mannitol, 3) symptoms suggestive of a relapse, 4) pregnancy 
or lactation, and 5) the time interval between the first GA 
injection and baseline assessment being .4 weeks.
ethical aspects
The protocol was submitted to the Independent Review 
Board, an approved ethical committee residing in Amster-
dam, the Netherlands. The committee concluded that, 
because of the observational design of the study, a review 
by an ethical committee was not required, as the study did 
not qualify for being tested according to the Dutch Medical 
Research involving Human Subjects Act of 1999.14 The study 
was performed in agreement with the Declaration of Helsinki 
(Ethical Principles for Medical Research Involving Human 
Subjects Version 2013; 64th World Medical Association 
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General Assembly, Fortaleza, Brazil, October 2013) (www.
wma.net) and the Wet medisch-wetenschappelijk onderzoek 
met mensen [Dutch Medical Research involving Human 
Subjects Act] (www.wetten.overheid.nl/BWBR0009408). 
Patients were informed that they had the right to discon-
tinue their participation or withdraw their consent at any 
time and were not obliged to state their reasons. They were 
informed that study discontinuation would not interfere with 
the care. The completion of the questionnaire about the care 
took ~15–20 minutes every 2 weeks, and the completion of 
the questionnaire about missed doses and treatment discon-
tinuation took ,5 minutes at twelve time points.
Technical aspects
The study was a modular application on the Curavista eHealth 
platform, built on an Oracle database with JAVA scripting, 
XML applets, and AJAX protocols. Data processing was 
256 bits encrypted with VPN tunneling. The databases were 
physically and software secured in a dedicated data center in 
the Netherlands. The database of the study was compliant with 
European Union (EU) regulations on data storage and activa-
tion for medical purposes. There were four separated databases: 
one with personal identifiers (name, address, and identification 
number), one with study records (answers to the questions and 
identification number), one with the social security number, 
and one with the key. Only after logging on, the data were 
presented as a whole on the screen (encrypted key).
Data acquisition
Data were acquired via the study website (www.cairstudie.nl). 
Patients logged on with a code provided by the study help 
desk and chose a username and a password. When online, 
they went through web pages containing the electronic case 
record forms (eCRFs). Patients were informed by email that 
an assessment was due and that the corresponding forms 
had been made available for completion. eCRFs were to be 
completed within 1 week. Completion could take as many 
sessions as needed, as answers were saved automatically. 
After confirmation by the patient, the eCRF was auto-
matically sent to the study center. Incomplete eCRFs were 
returned. In the case of an eCRF not being completed within 
1 week, the help desk reminded the patient by telephone.
Outcomes and assessment schedule
Persistence and adherence
At 12 time points – at 3 months, 6 months, 9 months, and 
12 months after the start of treatment and at eight random time 
points unknown to patients, neurologists, and nurses – the 
following data were reported by the patients: the number 
of missed doses in the preceding 14 days, the eventual 
discontinuation of GA, and the date of discontinuation 
(if applicable). Thus, patient-reported data were obtained 
covering 20 weeks of the 52-week study period. The distri-
bution of the assessments over the year was as follows: at 
4 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 26 weeks, 
32 weeks, 34 weeks, 38 weeks, 44 weeks, 48 weeks, and 
52 weeks after the start of treatment.
Multiple disciplines of care
Care provided by the following disciplines was assessed: 
neurologist, nurse, psychologist, pharmacist, rehabilitation 
doctor, general practitioner, other medical specialists, occu-
pational therapist, physiotherapist, social worker, dietician, 
home caregivers, informal caregivers, and other caregivers. 
Care was defined as visits to outpatient departments, hospital 
visits, contacts by telephone, contacts via the Internet, 
health-promoting activities that are coached or counseled 
by caregivers (eg, medical fitness), care received at home, 
or any other activity considered by the patient as such. Care 
received in the preceding 14 days was reported by patients 
at baseline and every 2 weeks thereafter up to week 52. For 
every discipline from which care was received, the number 
of care sessions and the time per care session (in minutes, 
by approximation) were documented. Thus, all care received 
during the 12-month study period was assessed.
Disease characteristics
At baseline, the treating neurologist or nurse provided the 
following data: the course of the disease, the duration of the 
disease, previous DMD treatment, and the number of relapses 
in the last 12 months and 24 months.
statistical analyses
Based on the patient-reported data, the percentage of missed 
doses was calculated. Against the background of reports in 
the literature, we first explored the number of nonadherent 
patients, using 85%, 90%, 95%, and 99% of the prescribed 
doses taken as cutoff points. The cutoff point that enabled 
the most meaningful analyses was used in the subsequent 
analyses. Based on the 2-weekly patient reports, we 
calculated the care frequency (number of contacts) and the 
care duration (minutes) over a 3-month (quarter [Q]) and the 
12-month study period for various disciplines. Comparisons 
were made between adherent and nonadherent patients and 
between persistent and nonpersistent patients using a two-
sided t-test (continuous variables) and a two-sided chi-square 
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test (dichotomous variables). The analyses focused on 
the neurological, nursing, psychological, pharmaceutical, 
and rehabilitative care disciplines, considering a P-value 
of ,0.05 as significant. The analyses of the care pro-
vided by the general practitioner, occupational therapist, 
physiotherapist, social worker, dietician, home caregivers, 
informal caregivers, other medical specialists, and other 
caregivers were secondary and explorative. To investigate 
whether treatment discontinuation was preceded by a relative 
lack of care, we related the number of neurological, nursing, 
psychological, pharmaceutical, and rehabilitative care con-
tacts and durations in a given quarter to discontinuation 
after that. Similar analyses were performed for the other 
care disciplines in an explorative way. To optimally identify 
care aspects that were specifically related to adherence, we 
analyzed the relationship between care and adherence in 
patients who were 12-month persistent.
Results
Demographic and disease characteristics
A total of 203 patients were included in the study. Three patients 
failed to complete a single questionnaire and were, therefore, 
removed from the data set. Of the resulting 200 analyzable 
patients, 157 (78.5%) patients were females and 43 (21.5%) 
patients were males (female-to-male ratio 3.65:1). The demo-
graphic and disease characteristics are presented in Table 1.
Persistence
One hundred twenty-four (62.00%) patients continued treat-
ment for at least 12 months, whereas 76 (38.00%) patients 
stopped treatment before the end of the study, yielding 
a 12-month persistence rate of 62%. The mean time at 
which treatment was discontinued was 6.4 months (SD 3.4, 
minimum 1.0, maximum 12.0). The female-to-male ratio 
did differ between persistent (4.17:1) and nonpersistent 
patients (3:1), in which female patients were more prone 
to continue treatment (P=0.035). The age did not differ 
between persistent (mean 39.9, SD 9.8, minimum 19.0, 
maximum 62.0 years) and nonpersistent (mean 39.2, SD 9.6, 
minimum 20.0, maximum 58.0 years) patients (P=0.60). 
Fifty-four (71.10%) of the 76 nonpersistent patients stated 
one or more reasons for their treatment discontinuation. Of a 
total of 62 reasons provided, 33 (53.23%) were side effects, 
12 (19.40%) were lack of effectiveness, and 17 (27.42) were 
other reasons.
Adherence
In the persistent group (N=124), we explored the number of 
adherent vs nonadherent patients by using 15%, 10%, 5%, 
and 1% missed doses as cutoff points, resulting in 85%, 90%, 
95%, and 99% adherence, respectively. Thus, of the persistent 
patients, 123 (99.19%) were 85% adherent, 115 (92.74%) 
were 90% adherent, 105 (84.68%) were 95% adherent, and 
59 (47.58%) were 99% adherent. To maximize our chances 
to find statistically significant and clinically relevant differ-
ences between adherent and nonadherent patients, we chose 
95% adherence as the cutoff point. Consequently, 105 (52%) 
patients were both persistent and adherent.
relationship between adherence and 
persistence
To investigate whether treatment discontinuation was pre-
ceded by nonadherence, we compared the adherence in Q1, 
Q2, and Q3 in patients who had discontinued treatment after 
Q1, Q2, and Q3, respectively, with the adherence in patients 
who had not discontinued in the corresponding quarters. 
Thus, we found an association between nonadherence in 
Q2 and discontinuation after Q2: nine (31.0%) of 29 Q2 
nonadherent patients discontinued treatment after Q2, 
whereas only eight (6.4%) of 126 Q2 adherent patients did 
so (P=0.0001). The association between nonadherence in 
Q3 and discontinuation in Q4 failed to be statistically sig-
nificant (P=0.0899), whereas no difference was found in Q1 
adherence between patients who had discontinued treatment 
after Q1 (adherent N=22 and nonadherent N=3) and those 
who had not discontinued after Q1 (adherent N=137 and 
nonadherent N=18) (P=0.9554).
relationship between care and persistence
To investigate whether treatment discontinuation was 
preceded by a relative lack of neurological, nursing, 
Table 1 Demographic and disease characteristics of patients 
(n=200)
Characteristic Mean, unless indicated 
otherwise
Female-to-male ratio 3.65:1
Age (years) 39.66 (sD 9.75, minimum 19, 
maximum 62)
Disease duration (years)  
(n=107)
4.48 (sD 4.96, minimum 0, 
maximum 18)
relapsing course  
(n=104 out of 112)
92.86%
secondary progressive  
course (n=10 out of 111)
9.01%
Previous disease-modifying  
treatment (n=40 out of 108)
37.04%
relapses in previous 12 months  
(n=113)
1.22 (sD 0.83, minimum 0, 
maximum 3)
relapses in previous 24 months  
(n=110)
1.64 (sD 1.05, minimum 0, 
maximum 6)
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psychological, pharmaceutical, or rehabilitative care, we 
calculated the care frequencies and durations in the quarter 
preceding discontinuation (Q1, Q2, and Q3) in patients who 
had discontinued treatment in Q2 (N=25), Q3 (N=17), and 
Q4 (N=14), respectively, and compared these with the data 
in patients who had not discontinued in the corresponding 
quarters (Q2 [N=154], Q3 [N=138], and Q4 [N=124], 
respectively). It was found that patients who discontinued 
treatment in Q4 had less-frequent (mean 0.07, SD 0.27, 
minimum 0, maximum 1) and shorter psychological care 
(mean 4.29, SD 16.04, minimum 0, maximum 60) in Q3 
than persistent patients (mean 0.47, SD 1.11, minimum 0, 
maximum 6 and mean 28.23, SD 69.68, minimum 0, maxi-
mum 375, respectively) (P=0.0018 and P=0.0022, respec-
tively). No other differences were found (all P.0.0467).
To explore whether treatment discontinuation was pre-
ceded by less-frequent or shorter care given by the general 
practitioner, occupational therapist, physiotherapist, social 
worker, dietician, home caregivers, informal caregivers, 
other medical specialists, and other caregivers, we made 
similar analyses for these disciplines. No differences were 
found (all P.0.05), except that patients who discontin-
ued in Q4 had received shorter care by other medical 
specialists than persistent patients (mean 7.14, SD 11.88, 
minimum 0, maximum 40 vs mean 46.90, SD 145.79, 
minimum 0, maximum 900) (P=0.0037).
relationship between care and adherence
In order to investigate aspects of care specifically related to 
adherence, we analyzed the relationship between multiple 
care disciplines and adherence in the persistent patient 
group (N=124). For neurological, nursing, psychological, 
pharmaceutical, and rehabilitative cares, we compared the 
care frequency (number of contacts) and the care duration 
(minutes) in the 12-month study period between adherent 
(N=105) and nonadherent (N=19) patients. No differences 
were found, neither in the care frequencies (all P.0.2942) 
nor in care durations (all P.0.2570) (Table 2). In addition, to 
explore the possibility that care given in a specific period, eg, 
in the first 3 months of treatment, was instrumental in bring-
ing about adherence, we also made comparisons with respect 
to quarterly care data. No differences between adherent and 
nonadherent patients were found either (all P.0.05).
The explorative analysis pertaining to the frequencies 
and durations of care given by the general practitioner, 
occupational therapist, physiotherapist, social worker, dieti-
cian, home caregivers, informal caregivers, other medical 
specialists, and other caregivers suggested that adherent 
patients had received more frequent home care (mean 1.06, 
SD 3.97, minimum 0, maximum 24) and more frequent infor-
mal care (mean 1.47, SD 5.24, minimum 0, maximum 25) 
than nonadherent patients (mean 0.00, SD 0.00, minimum 0, 
maximum 0 and mean 0.21, SD 0.63, minimum 0, maximum 
2, respectively) (P=0.0074 and P=0.0198, respectively). 
Similarly, the home care and informal care durations were 
longer in adherent (mean 211.90, SD 795.50, minimum 0, 
maximum 4,785 and mean 472.84, SD 2,126.78, minimum 0, 
maximum 15,275, respectively) than in nonadherent patients 
(mean 0.00, SD 0.00, minimum 0, maximum 0 and mean 
19.26, SD 82.52, minimum 0, maximum 360, respectively) 
(P=0.0074 and P=0.0318, respectively). No other differences 
were found (all P.0.05) (Table 3).
Then, to further explore whether home care or informal 
care given in a specific period was related to adherence, 
we compared the quarterly care data. Whereas nonadher-
ent patients (N=19) had received no home care (mentioned 
earlier), adherent patients reported quarterly home care in 
Q1, Q2, Q3, and Q4 (mean values 1.80, 1.80, 2.20, and 
Table 2 neurological, nursing, psychological, pharmaceutical, and rehabilitative care frequencies (number of contacts) and durations 
(minutes) in adherent vs nonadherent patients over the 12-month study period
Adherent patients (N=105) Nonadherent patients (N=19) Two-sided 
t-test (P-value)Mean SD Minimum Maximum Mean SD Minimum Maximum
care frequency (n)
neurologist 3.38 2.25 0 11 3.26 2.56 0 12 0.8525
nurse 4.76 4.22 0 22 5.21 4.76 0 21 0.7040
Psychologist 1.40 3.37 0 18 2.53 4.34 0 17 0.2942
Pharmacist 2.37 4.05 0 17 2.05 2.86 0 13 0.6798
rehabilitation 1.24 2.14 0 9 1.68 2.43 0 6 0.4607
care duration (minutes)
neurologist 68.97 59.15 0 280 95.26 87.60 15 350 0.2224
nurse 126.43 125.58 0 585 138.23 184.01 0 835 0.7910
Psychologist 86.86 228.63 0 1,525 169.74 294.88 0 1,140 0.2570
Pharmacist 22.42 42.71 0 230 24.89 44.75 0 200 0.8250
rehabilitation 50.05 163.37 0 1,570 40.79 52.16 0 140 0.6434
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2.20, respectively) (P=0.0349, P=0.0064, P=0.0091, and 
P=0.0180, respectively). The home care duration (minutes) 
in the adherent group ranged from 7 (mean) (SD 34.20, 
minimum 0, maximum 220) in Q1 to 25 (mean) (SD 117, 
minimum 0, maximum 780) in Q4 (P=0.0409, P=0.0064, 
P=0.0139, and P=0.0294, respectively). Similarly, the 
informal care frequencies in the first three quarters were 
significantly higher in adherent patients than in nonadher-
ent patients (mean values 0.10 vs 0.02 [P=0.0302], 0.11 vs 
0.02 [P=0.0329], and 0.13 vs 0.00 [P=0.0078]), as were the 
informal care durations (minutes) in all four quarters (mean 
values 30.55 vs 0.04 [P=0.0409], 43.65 vs 0.07 [P=0.0064], 
40.92 vs 0.00 [P=0.0130], and 40.92 vs 6.32 [P=0.0294]).
Discussion
In MS patients in their first year of treatment with GA 20 mg 
sc daily, we first observed that those who discontinued 
treatment in Q4 had less-frequent and shorter psychological 
care in Q3, whereas no association was found between dis-
continuation and neurological, nursing, pharmaceutical, and 
rehabilitative care in either quarter; second, no relationship 
was observed between the frequency or duration of neurologi-
cal, nursing, psychological, pharmaceutical, or rehabilitative 
care and adherence; and third, an association between the 
frequency and duration of home care and informal care and 
adherence was observed during explorative analyses.
According to the World Health Organization, adherence 
is “the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle 
changes–corresponds with agreed recommendations from a 
health care provider”.6 Given that drug treatments in chronic 
disorders are only optimally effective in the long term and 
with virtually no missed doses, the notion “adherence” 
has the following two aspects: the persistence of treatment 
(no discontinuation) and the application of the agreed dosing 
scheme (no missed doses). With respect to disease-modifying 
treatment in MS, however, the term adherence is also being 
used to specifically describe persistence,16 which may be 
confusing. We choose to use adherence in a strict sense, 
ie, adherence to dosing as agreed.17 This is in-line with 
adherence as defined by the International Society for Pharma-
coeconomics and Outcomes Research Medication Compli-
ance and Persistence Special Interest Group: “adherence is 
the percentage of doses taken as prescribed, over a set time 
period for analysis (either from the first to last medication 
dispensing date or for a fixed follow-up time frame)”.18
The 12-month persistence rate was 62%. In a comparable 
study, we observed a 12-month persistence of treatment with 
GA 20 mg sc daily of 71.6%.2 In an open-label observational 
study on a German cohort of 308 MS patients, GA’s persis-
tence rates at 6 months and 24 months of observation were 
91.1% and 67.1%, respectively.19
Table 3 Frequencies (number of contacts) and durations (minutes) of care given by general practitioners, occupational therapists, 
physiotherapists, social workers, dieticians, home caregivers, informal caregivers, other medical specialists, and other caregivers in 
adherent vs nonadherent patients over the 12-month study period
Adherent patients (N=105) Nonadherent patients (N=19) Two-sided 
t-test (P-value)Mean SD Minimum Maximum Mean SD Minimum Maximum
care frequency (n)
general practitioner 2.52 3.01 0 12 2.58 2.67 0 9 0.9360
Physiotherapist 8.88 9.28 0 26 9.68 9.76 0 25 0.7410
Occupation therapist 1.58 3.01 0 14 1.63 2.79 0 10 0.9433
social worker 1.35 2.55 0 12 1.21 1.96 0 6 0.7834
Dietician 0.32 1.58 0 13 0.79 2.07 0 7 0.3612
home caregivers 1.06 3.97 0 24 0.00 0.00 0 0 0.0074
informal caregivers 1.47 5.24 0 25 0.21 0.63 0 2 0.0198
Other specialists 2.04 3.41 0 18 2.89 3.09 0 11 0.2838
Other caregivers 3.02 4.33 0 24 1.84 3.29 0 12 0.1833
care duration (minutes)
general practitioner 43.51 77.58 0 580 51.63 64.36 0 201 0.6285
Physiotherapist 761.59 1,110.93 0 6,480 775.37 1,041.24 0 3,560 0.9585
Occupation therapist 95.76 198.66 0 1,020 101.84 208.21 0 795 0.9071
social worker 81.95 168.34 0 1,050 67.63 111.15 0 320 0.6398
Dietician 12.35 69.19 0 662 21.84 54.95 0 200 0.5122
home caregivers 211.90 795.47 0 4,785 0.00 0.00 0 0 0.0074
informal caregivers 472.84 2,126.78 0 15,275 19.26 82.52 0 360 0.0318
Other specialists 127.52 275.20 0 1,870 216.05 282.88 0 975 0.2193
Other caregivers 225.63 761.18 0 7,150 124.05 254.01 0 865 0.2850
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We observed that patients who discontinued treatment 
in Q4 had received less-frequent and shorter psychological 
care in Q3. Psychological problems, such as depression 
and anxiety, occur frequently in RRMS20 and are known to 
negatively affect adherence.21 It is conceivable that, in Q3, 
the effectiveness of the new treatment is provisionally evalu-
ated. Supposedly, in depressed or anxious patients, eventual 
doubts about effectiveness may lead more often to treatment 
discontinuation than in patients without these symptoms. 
In this context, the identification of depressed and anxious 
patients and their timely psychological treatment, therefore, 
may be thought to prevent discontinuation on improper 
grounds, especially after Q3.
The percentage of missed doses was low in our study, 
as 84.7% of the persistent patients had reportedly injected 
at least 95% of the prescribed doses and 99% of the patients 
at least 85% of the doses. This high adherence may result 
from study-related factors. First, the self-report method may 
overestimate adherence. Second, as patients were asked to 
report twelve times over a 1-year period, the number of doses 
they had missed in the preceding 2 weeks, the study partici-
pation will have led to an increased awareness in patients of 
adherence, helping them to not forget their injections. It has 
been known that “forgot to inject” is one of the main reasons 
for missing doses.21,22 Importantly, however, high adherence 
has also been reported in INFβ-1a-treated patients who used 
an autoinjector with electronic registration of injections: the 
mean (SD) cumulative adherence until the 12th month or 
treatment discontinuation was 97.1%±7.3%.22 Therefore, 
we hypothesize that, in our patients, an increased awareness, 
resulting from the frequent reporting of injected doses, is 
more likely to have caused the high adherence figure than 
the self-report method. Although our study suggests that 
frequent online self-reports on missed doses might improve 
adherence, we think that, in real life, this approach is not 
effective as the attrition rate, both in terms of discontinu-
ation and nonadherence to the online reporting scheme, is 
expectedly high.
The 80% cutoff is frequently used to define adequate 
adherence, also in MS.23 Yet it deserves to be questioned, as 
it means that one out of five doses is not taken. Given that a 
recent 15-year follow-up study of a randomized controlled 
trial suggests that higher cumulative exposure to sc IFNβ-1a 
may be associated with better clinical outcomes,8 the missing 
of 20% of the doses is likely to be clinically relevant. There-
fore, we propose to use 90% or 95% cutoff for determining 
adequate adherence, in agreement with Treadaway et al,21 
whose definition of nonadherence (missing any injection 
within the last 4 weeks) implies 92%, 93%, and 96% 
thresholds for sc INF-β-1a, INF-β-1b, and daily GA, 
respectively.
We obtained no evidence for associations between adher-
ence and the frequency or duration of care given by neurolo-
gists, nurses, psychologists, pharmacists, or rehabilitation 
doctors. In the explorative analyses, we found associations 
between home care and adherence and between informal care 
and adherence. We first assumed that patients who were not 
capable to self-inject due to motor, sensory, visual, or coordi-
native disabilities (as well as patients with a needle phobia or 
self-injection anxiety, well-known barriers to proper adher-
ence to GA) had the injections administered by home care or 
informal caregivers.24 However, as the highest home care fre-
quency reported was 24 (in 12 months) (mean 10.1, SD 8.0, 
median 10) and the highest informal care frequency reported 
was 25 (mean 8.8, SD 10.0, median 2.0), it is unlikely that 
the administration of injections explains the association with 
adherence. In addition, recent reports show that home care 
and informal care may otherwise improve adherence. The 
mere presence of a caregiver at home significantly improved 
medication adherence in older individuals with heart failure 
and mild cognitive impairment;25 about one-third of RRMS 
patients show cognitive impairment, including memory dis-
turbances.20 In an uncontrolled study on the effectiveness of 
a community-based weight reduction program, participants 
were requested to identify three family members and friends 
to sign a social support contract; independent risk factors for 
not completing the program were not having a family member 
or friend to sign a social support contract.26 In MS, it has been 
found that, in contrast to nonadherent patients, patients who 
were highly adherent perceived greater support from their 
spouse;21 and pilot data suggest that telephone counseling 
and home telehealth monitoring may improve adherence.27 
In all, the effect of home care and informal care on adher-
ence in MS patients, as suggested by our data, is most likely 
mediated via social processes.
Our study has several limitations. In view of the high 
adherence in our patients, it cannot be taken for granted that 
the findings apply to populations with lower adherence. Also, 
the geographical setting of the study (one country in Western 
Europe) and the relatively high overall quality of the health 
care28 warrant a careful extrapolation of the results to other 
societies or countries with different health care systems. 
Perhaps most important, we did not assess the quality of the 
care that was delivered, and it may well be that associations do 
exist between the knowledge, expertise, experience, or commu-
nicative skills of caregivers and persistence and adherence.
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Conclusion
In MS patients in their first year of treatment with GA 20 mg 
sc daily, we observed a 62% persistence rate with 85% of 
persistent patients being 95% adherent. Patients who stopped 
treatment in Q4 had received less-frequent and shorter psy-
chological care in Q3, whereas there were no associations 
between discontinuation and neurological, nursing, phar-
maceutical, and rehabilitative cares in either quarter. No 
relationship was found between the frequency or duration 
of neurological, nursing, psychological, pharmaceutical, 
or rehabilitative care and adherence. Explorative analyses 
suggest an association between the frequency and duration 
of home care and informal care and adherence.
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